NVIDIA Maintains Half-Trillion Revenue Target Amid Strong Demand, Navigates China Headwinds
Key Takeaways NVIDIA (NVDA) CFO Colette Kress confirmed the next-generation Rubin AI chips are on track for a H2 2026 […]
[DowJonesToday]Dow Jones Edges Up as Nvidia Earnings and Fed Outlook Dominate Investor Focus
The Dow Jones Industrial Average (^DJI) closed up 47.03 points, or 0.1020%, at 46138.77 on Wednesday, November 19, 2025, snapping
NVIDIA’s Blockbuster Q3 Earnings and Strong Q4 Outlook Ignite Tech Rally, Fueling AI Optimism
Key Takeaways NVIDIA (NVDA) reported record Q3 fiscal year 2026 revenue of $57.0 billion, significantly beating analyst expectations of around
Wall Street Rebounds as Nvidia Earnings Loom, Economic Data on Deck
The U.S. stock market experienced a notable rebound on Wednesday, November 19, 2025, as major indexes snapped multi-day losing streaks,
Market Closes Higher Amid Moderna Investment and UK Investor Exodus
Key Takeaways US major indices, the S&P 500 and NASDAQ, closed higher, gaining 0.37% and 0.59% respectively, signaling positive market
[DowJonesToday]Dow Jones Edges Higher as Nvidia Earnings Take Center Stage
The Dow Jones Industrial Average (^DJI) saw a modest gain today, closing up 47.03 (0.1020%) points at 46138.77. This performance
AI, Media Rights, and Chip Policy Dominate Wednesday’s Financial News
Key Takeaways Yann LeCun, a pioneering figure in AI and head of Meta's (META) AI research lab, is reportedly set
Market Rebounds Ahead of Nvidia Earnings and Key Economic Data
U.S. stock markets staged a modest rebound on Wednesday, November 19, 2025, with major indexes closing higher, breaking a multi-day
Market Movers: Motorola Solutions Expands AI Security, Nvidia Sees Bullish Bets, and FDA Approves New Lung Cancer Treatments
Key Takeaways Motorola Solutions (MSI) has significantly bolstered its enterprise security portfolio with the acquisition of Blue Eye, a leading
Market Snapshot: FDA Approvals, Geopolitical Shifts, and Major AI Investments Drive Headlines
Key Takeaways The FDA has granted significant approvals to Amgen (AMGN) and Bayer (BAYN) for lung cancer treatments, signaling crucial